1. Scrip
  2. >>Business
  3. >>Financing

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

Bain Previously Provided Up To $300m

 
• By Mandy Jackson

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

3D illustration of a human heart presented in geometric shapes consisting of white lines scattered around its periphery
Cardurion's series B also will fund drug discovery and business development • Source: Shutterstock

Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidates as well as in-house discovery work and external sourcing of novel drug candidates. The company’s clinical-stage programs came from outside sources, and it continues to search for first-in-class cardiovascular disease medicines at a time when dealmaking in the cardiometabolic space is getting increasingly competitive.

Key Takeaways

  • Cardurion raised $260m in series B venture capital to fund Phase II clinical trials of its PDE9 inhibitor in heart failure and its CaMKII inhibitor in a rare genetic arrhythmic disease.

“No question, there is renewed interest in the space,” Cardurion CEO Peter Lawrence told Scrip. But while cardiovascular drug development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.